Table 1.
Results of patient allocation
| Allocation Factor | 10≤Hb<11 | 11≤Hb<12 | ||
|---|---|---|---|---|
| VPS-HA Group | PS-Con Group | VPS-HA Group | PS-Con Group | |
| Age (yr) | ||||
| ≤65 | 55 | 46 | 19 | 30 |
| >65 | 40 | 53 | 37 | 25 |
| Sex | ||||
| Men | 61 | 54 | 36 | 45 |
| Women | 34 | 45 | 20 | 10 |
| Serum ferritin (ng/ml) | ||||
| ≤100 | 70 | 65 | 28 | 30 |
| >100 | 25 | 34 | 28 | 25 |
| Diabetes | ||||
| With | 28 | 40 | 14 | 16 |
| Without | 67 | 59 | 42 | 39 |
| Type of erythropoiesis-stimulating agent | ||||
| DA | 38 | 44 | 27 | 25 |
| rHuEPO | 57 | 55 | 29 | 30 |
| Total | 95 | 99 | 56 | 55 |
Each patient was allocated to target hemoglobin range depending on one's prestudy level of hemoglobin measured for 3 months, and the target hemoglobin level was kept during this trial. Hb, hemoglobin; VPS-HA, vitamin E-bonded high-flux polysulfone dialysis membrane; PS-con, type 4 polysulfone dialysis membrane; DA, darbepoetin alfa; rHuEPO, human recombinant erythropoietin.